StrandSmart
Next generation, cell-based liquid biopsy
Overview
Raised: $35,873
Rolling Commitments ($USD)
03/30/2023
$588
33
2017
Healthcare & Pharmaceuticals
HealthTech
B2B
Medium
High
Summary Profit and Loss Statement
FY 2021 | FY 2020 | |
---|---|---|
Revenue |
$0 |
$0 |
COGS |
$0 |
$0 |
Tax |
$0 |
$0 |
| ||
| ||
Net Income |
$-1,183,711 |
$-1,204,291 |
Summary Balance Sheet
FY 2021 | FY 2020 | |
---|---|---|
Cash |
$164,677 |
$506,897 |
Accounts Receivable |
$0 |
$0 |
Total Assets |
$182,683 |
$522,007 |
Short-Term Debt |
$167,939 |
$400,513 |
Long-Term Debt |
$5,498,437 |
$4,425,437 |
Total Liabilities |
$5,666,376 |
$4,825,950 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual